Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases
US-2024409487-A1 · Dec 12, 2024 · US
US10383839B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10383839-B2 |
| Application number | US-201213495049-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 13, 2012 |
| Priority date | Jun 30, 2011 |
| Publication date | Aug 20, 2019 |
| Grant date | Aug 20, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
Opening claim text (preview).
What is claimed is: 1. An ophthalmic device for the treatment of ocular conditions comprising: a silicone hydrogel contact lens incorporating an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediatory and a monohydric alcohol selected from the group consisting of eicosapentaenoic acid ethyl ester and alpha-linolenic acid ethyl ester and mixtures thereof; wherein the ophthalmic device is contained in a sealed package in which the silicone hydrogel contact lens incorporating the ester of the anti-inflammatory lipid mediator is stored in the presence of a packing solution. 2. The ophthalmic device of claim 1 , wherein the ester or amide is present in the silicone hydrogel contact lens in a therapeutically effective amount. 3. The ophthalmic device of claim 1 , wherein the ester is present in the silicone hydrogel contact lens in an amount in the range of about 0.01% to 0.5% by weight. 4. The ophthalmic device of claim 1 , wherein the packing solution is water-based. 5. The ophthalmic device of claim 4 , wherein the packing solution further comprises one or more of the following: a surfactant, a wetting agent, a chelant, and an antioxidant. 6. The ophthalmic device of claim 5 , wherein the packing solution further comprises one or more ingredients selected from the group consisting of Tyloxapol™, methyl gluceth-20, Vitamin E, diethylenetriaminepentaacetic acid, boric acid, sodium borate, and sodium chloride. 7. The ophthalmic device of claim 1 , wherein upon wearing of the silicone hydrogel contact lens on-eye, the ester releases over time. 8. The ophthalmic device of claim 7 comprising a release rate of approximately 3 micrograms per hour after a first hour of wearing. 9. The ophthalmic device of claim 1 , wherein the ester is incorporated into the silicone hydrogel contact lens in an amount in the range of about 50 to about 620 micrograms per lens. 10. The ophthalmic device of claim 1 , wherein the silicone hydrogel contact lens is selected from the group consisting of balafilcon, acquafilcon, lotrafilcon, comfilcon, galyfilcon, senofilcon narafilcon, falcon II 3, or asmofilcon A. 11. The ophthalmic device of claim 1 wherein the ester is eicosapentaenoic acid ethyl ester. 12. The ophthalmic device of claim 1 wherein the ester is alpha-linolenic acid ethyl ester.
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Artificial tears; Irrigation solutions · CPC title
Ophthalmic agents · CPC title
Drugs for disorders of the senses · CPC title
Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.